Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nadia Awad

Vascular Surgery Camden, NJ Medical Doctor

NPI 1205065695 CMS profile 280859

3 Cooper Plz, Suite 403, Camden, NJ 08103

Open in the dashboard

General payments

$16,384

193 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nadia Awad of Camden, NJ is reported in the CMS Open Payments database as having received $16,384 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,424 35
2024 General $1,589 40
2023 General $3,109 52
2022 General $1,027 26
2021 General $802 14
2020 General $6,445 11
2019 General $988 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nadia Awad
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Nadia Awad were reported at $2,424. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Nadia Awad Vascular Surgery median Middle half National median
2019 $988 $796 $226–$2,363 $163
2020 $6,445 $348 $118–$1,110 $114
2021 $802 $471 $158–$1,421 $132
2022 $1,027 $725 $222–$2,183 $149
2023 $3,109 $836 $257–$2,440 $160
2024 $1,589 $909 $252–$2,619 $164
2025 $2,424 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $6,029 3 payments
  2. W. L. Gore & Associates, Inc. $3,894 38 payments
  3. Medtronic, Inc. $2,298 38 payments
  4. Boston Scientific Corporation $1,152 14 payments
  5. Shockwave Medical, Inc $1,001 43 payments
  6. Smith+Nephew, Inc. $381 18 payments
  7. Medtronic Vascular, Inc. $275 4 payments
  8. Cook Medical LLC $253 4 payments
  9. Endologix, Inc. $174 3 payments
  10. Silk Road Medical, Inc. $154 2 payments
  11. Other $772 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,009 178 payments
  2. Education $6,000 2 payments
  3. Travel and Lodging $1,375 13 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $6,029 3 payments
  2. ENDURANT IIS $1,746 31 payments
  3. GORE TAG Thoracic Endoprosthesis $1,024 10 payments
  4. GORE VIABAHN VBX Balloon Expandable Endo $972 7 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $868 41 payments
  6. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $706 12 payments
  7. Endurant $429 6 payments
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $359 2 payments
  9. General - Vascular Intervention $274 2 payments
  10. ELUVIA $244 3 payments
  11. Other $4,023 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

71

Median for Vascular Surgery: 122

Drug cost

$1,677

Median for Vascular Surgery: $14,135

Branded share of claims

35.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cilostazol Generic 28 $797
Gabapentin Generic 18 $453
Clopidogrel Clopidogrel Bisulfate Brand 25 $428

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$84,829

Medicare's payments for the services billed

Medicare patients

311

Average age 73

Services billed

629

146 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Arthritis 56%
Diabetes 54%
Chronic kidney disease 49%
Heart failure 41%
Atrial fibrillation 34%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record